External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Haematology Relapsed refractory multiple myeloma

Relapsed refractory multiple myeloma

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Dec 9 / Roche and Genentech
Biomarker correlates and clinical activity of cevostamab in patients with triple-class refractory multiple myeloma who have received >=1 prior B-cell maturation antigen-targeted bispecific antibody: results from the Phase I/II CAMMA 2 study
CAMMA 2 is a Phase I/II study of cevostamab monotherapy in patients with triple-class refractory multiple myeloma, who have received prior B-cell maturation antigen-targeted bispecific antibodies. Initial results and an exploratory analysis of baseline patient and tumor-related factors are presented.
Haematology Oncology Relapsed refractory multiple myeloma ASH-2024

Sign up or login to unlock the full suite of MEDICALLY features
Dec 9 / Roche and Genentech
Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma: Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies
GO39775 is an ongoing Phase I dose-escalation and dose-expansion study of cevostamab monotherapy in patients with heavily pre-treated relapsed/refractory multiple myeloma. This abstract reports the updated efficacy and safety data from patients who received cevostamab once every 3 weeks at the 160mg target-dose level.
Haematology Oncology Relapsed refractory multiple myeloma ASH-2024

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.